iRadimed (IRMD) Financials

$70.52 -1.86 (-2.57%)

Closing price 09/19/2025 04:00 PM Eastern

Extended Trading

$70.53 +0.01 (+0.01%)

As of 09/19/2025 07:21 PM Eastern

Annual Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	2.05	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19
Consolidated Net Income / (Loss)	2.05	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19
Net Income / (Loss) Continuing Operations	2.05	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19
Total Pre-Tax Income	3.02	12	11	1.40	6.20	9.04	-0.62	9.84	16	22	24
Total Operating Income	3.07	12	11	1.29	6.00	8.65	-0.76	9.82	16	20	22
Total Gross Profit	12	26	26	18	23	30	24	32	41	50	56
Total Revenue	16	32	32	23	30	39	32	42	53	66	73
Operating Revenue	16	32	32	23	30	39	32	42	53	66	73
Total Cost of Revenue	3.40	5.84	6.15	5.57	7.21	8.82	8.14	9.76	12	15	17
Operating Cost of Revenue	3.40	5.84	6.15	5.57	7.21	8.82	8.14	9.76	12	15	17
Total Operating Expenses	9.18	14	15	16	17	21	24	22	26	30	34
Selling, General & Admin Expense	4.82	7.77	8.80	9.00	8.71	10	12	9.77	11	15	16
Marketing Expense	3.30	4.71	5.28	5.50	7.00	9.17	10	11	13	12	16
Research & Development Expense	1.07	1.76	1.35	1.72	1.52	1.43	1.90	1.91	2.28	2.86	2.83
Total Other Income / (Expense), net	-0.05	0.12	0.03	0.11	0.19	0.40	0.14	0.02	0.55	1.70	2.31
Other Income / (Expense), net	-0.05	0.12	0.03	0.11	0.19	0.40	0.14	0.02	0.55	1.70	2.31
Income Tax Expense	0.97	4.10	3.74	0.90	-0.11	-0.59	-1.99	0.51	3.35	4.55	5.04
Basic Earnings per Share	$0.23	$0.68	$0.67	$0.05	$0.59	$0.85	$0.11	$0.76	$1.02	$1.36	$1.52
Weighted Average Basic Shares Outstanding	8.74M	11.00M	10.82M	10.64M	10.76M	11.28M	12.12M	12.35M	12.56M	12.60M	12.67M
Diluted Earnings per Share	$0.20	$0.60	$0.60	$0.04	$0.52	$0.78	$0.11	$0.74	$1.02	$1.35	$1.50
Weighted Average Diluted Shares Outstanding	10.22M	12.56M	11.99M	11.72M	12.11M	12.28M	12.44M	12.59M	12.64M	12.72M	12.78M
Weighted Average Basic & Diluted Shares Outstanding	8.90M	11.10M	10.80M	10M	11.00M	11.92M	12.31M	12.56M	12.59M	12.66M	12.72M

This table shows iRadimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77
Consolidated Net Income / (Loss)	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77
Net Income / (Loss) Continuing Operations	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77
Total Pre-Tax Income	4.70	4.35	5.30	6.41	5.68	5.24	6.27	6.42	6.34	5.95	7.33
Total Operating Income	4.25	4.01	4.96	5.91	5.16	4.75	5.63	5.79	5.80	5.43	6.79
Total Gross Profit	11	12	12	13	13	13	14	14	15	15	16
Total Revenue	15	15	16	17	17	18	18	18	19	20	20
Operating Revenue	15	15	16	17	17	18	18	18	19	20	20
Total Cost of Revenue	3.64	3.75	3.94	3.67	4.04	4.21	3.92	4.13	4.63	4.67	4.45
Operating Cost of Revenue	3.64	3.75	3.94	3.67	4.04	4.21	3.92	4.13	4.63	4.67	4.45
Total Operating Expenses	6.97	7.71	7.22	6.93	8.25	8.64	8.38	8.40	8.96	9.41	9.17
Selling, General & Admin Expense	2.70	3.92	3.31	3.62	4.27	3.99	4.10	3.97	3.87	4.61	4.28
Marketing Expense	3.67	0.79	2.95	2.86	5.54	3.83	3.48	3.80	7.52	4.18	4.01
Research & Development Expense	0.60	3.00	0.96	0.45	-1.56	0.82	0.80	0.64	-2.44	0.62	0.88
Total Other Income / (Expense), net	0.45	0.34	0.34	0.50	0.52	0.50	0.64	0.63	0.54	0.51	0.54
Other Income / (Expense), net	0.45	0.34	0.34	0.50	0.52	0.50	0.64	0.63	0.54	0.51	0.54
Income Tax Expense	1.03	0.94	1.12	1.34	1.14	1.11	1.37	1.37	1.20	1.26	1.55
Basic Earnings per Share	$0.29	$0.27	$0.33	$0.40	$0.36	$0.33	$0.39	$0.40	$0.40	$0.37	$0.45
Weighted Average Basic Shares Outstanding	12.56M	12.59M	12.60M	12.60M	12.60M	12.66M	12.66M	12.67M	12.67M	12.71M	12.72M
Diluted Earnings per Share	$0.29	$0.27	$0.33	$0.40	$0.35	$0.32	$0.38	$0.40	$0.40	$0.37	$0.45
Weighted Average Diluted Shares Outstanding	12.64M	12.69M	12.72M	12.74M	12.72M	12.75M	12.76M	12.78M	12.78M	12.83M	12.84M
Weighted Average Basic & Diluted Shares Outstanding	12.59M	12.59M	12.60M	12.61M	12.66M	12.66M	12.67M	12.67M	12.72M	12.72M	12.72M

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	6.99	9.91	-1.65	0.49	9.82	15	6.59	12	-4.04	-8.20	2.47
Net Cash From Operating Activities	2.92	7.65	9.41	3.42	7.38	10	5.82	11	10	13	26
Net Cash From Continuing Operating Activities	2.59	7.65	9.41	3.42	7.38	10	5.82	11	10	13	26
Net Income / (Loss) Continuing Operations	2.05	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19
Consolidated Net Income / (Loss)	2.05	7.53	7.21	0.50	6.30	9.63	1.37	9.33	13	17	19
Depreciation Expense	0.15	0.81	0.96	1.31	1.11	1.24	1.34	1.41	0.67	0.77	0.82
Non-Cash Adjustments To Reconcile Net Income	0.69	1.34	2.04	2.75	1.93	1.93	3.90	1.62	1.59	2.61	2.52
Changes in Operating Assets and Liabilities, net	-0.30	-2.03	-0.80	-1.14	-1.97	-2.57	-0.79	-1.07	-5.02	-7.11	3.05
Net Cash From Investing Activities	-8.30	-0.06	-1.94	-1.02	1.52	3.20	0.25	0.65	-1.37	-8.01	-8.82
Net Cash From Continuing Investing Activities	-8.30	-0.06	-1.94	-1.02	1.52	3.20	0.25	0.65	-1.37	-8.01	-8.82
Purchase of Property, Plant & Equipment	-0.61	-0.31	-1.52	-0.82	-0.26	-0.49	-0.64	-0.74	-1.87	-8.01	-8.82
Net Cash From Financing Activities	13	2.33	-9.12	-1.90	0.93	2.02	0.52	0.02	-13	-14	-14
Net Cash From Continuing Financing Activities	13	2.33	-9.12	-1.90	0.93	2.02	0.52	0.02	-13	-14	-14
Payment of Dividends	-	-	-	-	-	-	-	0.00	-13	-13	-14
Other Financing Activities, net	0.17	1.73	0.60	-0.16	0.93	-0.47	-1.21	0.02	-0.15	-0.43	-0.66
Cash Income Taxes Paid	1.18	2.70	3.39	1.21	1.38	0.01	0.00	0.97	1.71	5.35	6.51

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	2.37	-15	3.05	0.92	3.02	-4.64	3.41	3.19	0.51	-1.90	2.66
Net Cash From Operating Activities	3.04	4.65	3.51	1.39	3.91	3.88	6.64	9.12	5.99	4.29	7.75
Net Cash From Continuing Operating Activities	3.06	4.65	3.51	1.39	3.91	3.88	6.64	9.03	6.08	4.29	7.75
Net Income / (Loss) Continuing Operations	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77
Consolidated Net Income / (Loss)	3.67	3.41	4.18	5.07	4.54	4.14	4.90	5.05	5.15	4.69	5.77
Depreciation Expense	-0.69	0.18	0.19	0.19	0.21	0.23	0.20	0.20	0.19	0.19	0.21
Non-Cash Adjustments To Reconcile Net Income	0.56	0.81	0.65	0.57	0.59	0.63	0.74	0.02	1.13	0.77	0.76
Changes in Operating Assets and Liabilities, net	-0.48	0.25	-1.50	-4.43	-1.42	-1.11	0.80	3.75	-0.40	-1.36	1.00
Net Cash From Investing Activities	-0.47	-6.56	-0.38	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06	-3.92	-2.82
Net Cash From Continuing Investing Activities	-0.47	-6.56	-0.38	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06	-3.92	-2.82
Purchase of Property, Plant & Equipment	-0.47	-6.56	-0.38	-0.44	-0.63	-0.48	-1.27	-4.01	-3.06	-3.92	-2.82
Net Cash From Financing Activities	-0.20	-13	-0.09	-0.03	-0.26	-8.04	-1.96	-1.92	-2.42	-2.28	-2.26
Net Cash From Continuing Financing Activities	-0.20	-13	-0.09	-0.03	-0.26	-8.04	-1.96	-1.92	-2.42	-2.28	-2.26
Payment of Dividends	-	-13	-	-	-	-7.98	-1.90	-1.90	-1.90	-2.16	-2.16
Other Financing Activities, net	-0.20	-0.05	-0.09	-0.03	-0.26	-0.06	-0.06	-0.02	-0.52	-0.12	-0.10
Cash Income Taxes Paid	0.95	0.00	2.76	1.38	1.22	0.19	2.82	1.45	2.06	0.01	2.34

This table presents iRadimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	23	35	37	39	48	67	71	83	86	92	98
Total Current Assets	22	34	34	35	45	59	64	76	77	76	75
Cash & Equivalents	9.45	19	18	18	28	43	50	62	58	50	52
Accounts Receivable	1.96	3.86	3.78	3.78	4.21	7.29	4.57	5.14	13	12	11
Inventories, net	2.13	2.38	3.89	4.21	4.06	3.64	3.93	4.30	5.37	13	10
Prepaid Expenses	0.28	0.32	0.36	0.65	0.53	0.41	0.77	1.00	0.63	1.19	1.51
Current Deferred & Refundable Income Taxes	0.44	0.42	0.15	0.13	1.37	1.37	2.48	3.31	0.25	-	0.54
Plant, Property, & Equipment, net	0.79	0.91	1.46	1.87	1.87	2.05	2.12	2.07	2.40	9.29	17
Total Noncurrent Assets	0.35	0.39	1.88	2.04	2.03	5.71	5.21	4.57	5.62	6.87	6.27
Intangible Assets	0.25	0.19	0.92	0.89	0.83	0.86	0.96	1.12	2.07	2.52	3.10
Noncurrent Deferred & Refundable Income Taxes	0.08	0.09	0.79	0.95	1.09	1.66	1.27	0.77	0.70	2.12	2.82
Other Noncurrent Operating Assets	0.02	0.10	0.17	0.20	0.11	3.19	2.98	2.68	2.85	2.22	0.35
Total Liabilities & Shareholders' Equity	23	35	37	39	48	67	71	83	86	92	98
Total Liabilities	2.42	3.31	5.31	6.08	6.50	11	9.68	11	12	21	12
Total Current Liabilities	2.28	2.89	3.66	4.08	4.69	5.86	4.92	6.82	8.55	16	8.51
Accounts Payable	0.63	1.01	1.12	0.66	0.77	0.99	0.66	0.78	1.80	1.86	1.90
Accrued Expenses	0.03	0.03	0.04	0.06	0.07	0.08	0.09	0.11	0.09	0.12	0.12
Current Deferred Revenue	0.31	0.53	1.03	1.62	1.80	1.67	1.95	2.55	3.37	2.57	2.26
Current Employee Benefit Liabilities	1.24	1.29	1.04	1.51	1.80	2.17	1.71	2.81	2.87	2.78	3.77
Other Taxes Payable	0.07	0.03	0.12	0.11	0.13	0.60	0.10	0.14	0.12	0.10	0.16
Other Current Liabilities	-	-	0.12	0.11	0.11	0.35	0.40	0.42	0.29	0.68	0.30
Total Noncurrent Liabilities	0.14	0.42	1.64	2.00	1.81	5.35	4.76	3.88	3.29	4.41	2.99
Noncurrent Deferred Revenue	0.14	0.42	1.64	2.00	1.81	2.63	2.31	1.68	1.38	2.79	2.99
Other Noncurrent Operating Liabilities	-	-	-	-	-	2.72	2.46	2.21	1.91	1.62	0.00
Total Equity & Noncontrolling Interests	21	32	32	33	42	56	61	72	74	71	87
Total Preferred & Common Equity	21	32	32	33	42	56	61	72	74	71	87
Total Common Equity	21	32	32	33	42	56	61	72	74	71	87
Common Stock	16	19	12	13	15	19	24	25	26	28	30
Retained Earnings	5.13	13	20	20	27	36	38	47	47	43	57

This table presents iRadimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025
Total Assets	76	80	76	81	87	88	90	94	102	106
Total Current Assets	68	72	61	66	72	72	74	74	75	77
Cash & Equivalents	52	56	43	46	47	45	49	52	50	53
Accounts Receivable	8.38	11	12	11	13	13	12	10	13	11
Inventories, net	4.86	5.24	6.31	8.42	12	13	12	11	11	11
Prepaid Expenses	0.80	0.39	0.68	0.77	0.74	1.04	1.02	0.95	1.54	1.92
Current Deferred & Refundable Income Taxes	2.30	0.00	0.00	0.00	0.00	-	-	-	-	0.33
Plant, Property, & Equipment, net	2.24	2.29	8.64	8.72	8.89	9.45	10	14	20	23
Total Noncurrent Assets	4.99	5.38	5.68	6.62	6.59	6.68	5.90	5.80	6.21	6.14
Intangible Assets	1.54	1.88	2.21	2.35	2.46	2.67	2.75	2.89	3.26	3.37
Noncurrent Deferred & Refundable Income Taxes	0.90	0.99	0.62	1.77	1.80	1.88	2.59	2.46	2.69	2.56
Other Noncurrent Operating Assets	2.55	2.51	2.85	2.50	2.32	2.12	0.56	0.45	0.27	0.20
Total Liabilities & Shareholders' Equity	76	80	76	81	87	88	90	94	102	106
Total Liabilities	9.83	9.77	11	12	13	12	10	11	12	12
Total Current Liabilities	6.14	5.60	6.76	7.59	7.88	7.62	7.46	8.06	8.47	8.81
Accounts Payable	0.82	0.96	1.76	2.55	2.78	1.29	1.12	1.40	2.59	1.90
Accrued Expenses	0.10	0.10	0.10	0.11	0.11	0.12	0.12	0.12	0.12	0.12
Current Deferred Revenue	2.29	1.59	2.07	1.71	1.92	2.34	2.54	2.56	2.60	3.26
Current Employee Benefit Liabilities	2.27	2.35	1.62	2.33	2.29	2.14	2.90	3.28	2.27	3.21
Other Taxes Payable	0.24	0.18	0.06	0.22	0.10	0.14	0.16	0.19	0.26	0.32
Other Current Liabilities	0.42	0.43	0.66	0.66	0.67	0.67	0.62	0.51	0.06	0.00
Total Noncurrent Liabilities	3.69	4.17	4.52	4.85	4.96	4.28	2.82	2.75	3.20	3.33
Noncurrent Deferred Revenue	1.63	2.18	2.59	3.01	3.23	2.76	2.82	2.75	3.20	3.33
Other Noncurrent Operating Liabilities	2.06	1.99	1.94	1.83	1.72	1.52	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	66	70	64	69	75	76	80	83	90	94
Total Preferred & Common Equity	66	70	64	69	75	76	80	83	90	94
Total Common Equity	66	70	64	69	75	76	80	83	90	94
Common Stock	26	26	27	27	28	29	29	30	31	31
Retained Earnings	40	44	37	42	47	47	50	54	59	63

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	38.03%	101.84%	2.86%	-28.97%	31.88%	26.54%	-17.65%	31.83%	27.48%	23.00%	11.71%
EBITDA Growth	8.33%	292.93%	-4.29%	-77.28%	169.94%	40.85%	-92.98%	1,457.33%	49.88%	33.54%	11.51%
EBIT Growth	8.39%	285.59%	-5.86%	-87.25%	343.81%	45.92%	-106.82%	1,694.53%	64.50%	34.35%	11.67%
NOPAT Growth	7.43%	257.66%	-3.47%	-93.61%	1,227.80%	50.81%	-105.75%	1,858.64%	33.11%	27.89%	9.83%
Net Income Growth	5.86%	267.25%	-4.19%	-93.07%	1,161.29%	52.79%	-85.79%	581.19%	37.56%	34.02%	11.87%
EPS Growth	-9.09%	200.00%	0.00%	-93.33%	1,200.00%	50.00%	-85.90%	572.73%	37.84%	32.35%	11.11%
Operating Cash Flow Growth	97.79%	162.31%	22.97%	-63.68%	115.93%	38.73%	-43.15%	93.52%	-10.80%	34.08%	90.30%
Free Cash Flow Firm Growth	0.00%	368.92%	-1.09%	-98.66%	6,321.75%	46.31%	-108.82%	1,466.98%	-29.77%	-69.70%	547.14%
Invested Capital Growth	29.45%	40.88%	25.13%	6.12%	14.85%	22.54%	1.43%	2.83%	62.44%	88.61%	16.71%
Revenue Q/Q Growth	0.00%	19.77%	-7.96%	3.20%	5.67%	7.09%	-6.88%	8.64%	5.94%	4.11%	2.72%
EBITDA Q/Q Growth	0.00%	42.97%	-15.59%	-12.63%	11.72%	5.10%	-69.32%	28.54%	3.12%	9.10%	2.67%
EBIT Q/Q Growth	0.00%	37.05%	-14.12%	-25.70%	15.77%	5.58%	-157.50%	33.15%	10.90%	4.71%	2.81%
NOPAT Q/Q Growth	0.00%	39.78%	-15.25%	-66.86%	31.24%	18.79%	-117.18%	53.92%	-4.34%	5.33%	3.46%
Net Income Q/Q Growth	0.00%	39.55%	-14.91%	-65.70%	31.87%	18.96%	-65.54%	53.63%	-1.68%	5.30%	3.26%
EPS Q/Q Growth	0.00%	39.53%	-13.04%	-66.67%	33.33%	18.18%	-65.63%	54.17%	-1.92%	4.65%	3.45%
Operating Cash Flow Q/Q Growth	-31.46%	22.04%	17.68%	-19.41%	40.90%	4.14%	-19.98%	8.37%	-3.16%	6.94%	8.81%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-6.42%	-93.79%	91.61%	0.72%	-155.53%	5.50%	-13.57%	37.40%	-3.72%
Invested Capital Q/Q Growth	0.00%	5.73%	-9.04%	-4.90%	-15.02%	0.71%	-15.24%	12.80%	10.81%	6.51%	9.06%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.25%	81.51%	81.06%	75.87%	76.31%	77.11%	74.33%	76.65%	77.45%	76.50%	76.94%
EBITDA Margin	20.23%	39.38%	36.65%	11.72%	23.99%	26.70%	2.28%	26.89%	31.61%	34.32%	34.26%
Operating Margin	19.59%	36.44%	33.60%	5.57%	19.72%	22.45%	-2.38%	23.48%	29.32%	30.56%	29.99%
EBIT Margin	19.28%	36.83%	33.70%	6.05%	20.36%	23.48%	-1.94%	23.52%	30.36%	33.16%	33.14%
Profit (Net Income) Margin	13.10%	23.83%	22.20%	2.17%	20.71%	25.00%	4.32%	22.30%	24.07%	26.22%	26.26%
Tax Burden Percent	67.95%	64.72%	65.87%	35.79%	101.71%	106.50%	-221.92%	94.81%	79.28%	79.09%	79.23%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	32.05%	35.28%	34.13%	64.21%	-1.71%	-6.50%	0.00%	5.19%	20.72%	20.91%	20.77%
Return on Invested Capital (ROIC)	66.73%	175.63%	128.76%	7.19%	86.26%	109.36%	-5.67%	97.57%	97.62%	69.89%	54.20%
ROIC Less NNEP Spread (ROIC-NNEP)	67.06%	175.27%	128.68%	7.03%	85.62%	108.31%	-9.53%	97.54%	96.89%	67.19%	50.31%
Return on Net Nonoperating Assets (RNNOA)	-51.15%	-147.12%	-106.16%	-5.64%	-69.43%	-89.60%	8.01%	-83.61%	-80.03%	-46.19%	-29.89%
Return on Equity (ROE)	15.58%	28.51%	22.61%	1.54%	16.84%	19.76%	2.34%	13.96%	17.59%	23.70%	24.31%
Cash Return on Invested Capital (CROIC)	41.06%	141.69%	106.44%	1.25%	72.44%	89.10%	-7.08%	94.78%	50.03%	8.49%	38.78%
Operating Return on Assets (OROA)	19.92%	39.74%	30.24%	3.66%	14.17%	15.70%	-0.90%	12.78%	19.22%	24.47%	25.49%
Return on Assets (ROA)	13.54%	25.72%	19.92%	1.31%	14.42%	16.72%	1.99%	12.12%	15.24%	19.35%	20.20%
Return on Common Equity (ROCE)	15.58%	28.51%	22.61%	1.54%	16.84%	19.76%	2.34%	13.96%	17.59%	23.70%	24.31%
Return on Equity Simple (ROE_SIMPLE)	9.81%	23.58%	22.62%	1.52%	15.03%	17.35%	2.23%	12.92%	17.41%	24.07%	22.15%
Net Operating Profit after Tax (NOPAT)	2.08	7.45	7.19	0.46	6.11	9.21	-0.53	9.31	12	16	17
NOPAT Margin	13.31%	23.58%	22.13%	1.99%	20.06%	23.91%	-1.67%	22.26%	23.24%	24.17%	23.76%
Net Nonoperating Expense Percent (NNEP)	-0.33%	0.35%	0.08%	0.15%	0.65%	1.05%	3.87%	0.03%	0.73%	2.70%	3.89%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	22.19%	20.05%
Cost of Revenue to Revenue	21.75%	18.49%	18.94%	24.13%	23.69%	22.89%	25.67%	23.35%	22.55%	23.50%	23.06%
SG&A Expenses to Revenue	30.77%	24.59%	27.07%	39.00%	28.62%	27.13%	38.68%	23.37%	20.07%	23.07%	21.76%
R&D to Revenue	6.83%	5.58%	4.15%	7.46%	4.98%	3.72%	6.00%	4.56%	4.27%	4.36%	3.87%
Operating Expenses to Revenue	58.66%	45.07%	47.46%	70.30%	56.58%	54.66%	76.71%	53.17%	48.13%	45.95%	46.95%
Earnings before Interest and Taxes (EBIT)	3.02	12	11	1.40	6.20	9.04	-0.62	9.84	16	22	24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3.17	12	12	2.71	7.30	10	0.72	11	17	23	25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.22	9.05	3.47	4.52	5.94	4.50	4.24	7.36	4.59	8.27	8.00
Price to Tangible Book Value (P/TBV)	6.29	9.10	3.58	4.65	6.06	4.57	4.31	7.47	4.72	8.58	8.30
Price to Revenue (P/Rev)	8.30	9.15	3.41	6.45	8.18	6.49	8.21	12.70	6.34	9.01	9.49
Price to Earnings (P/E)	63.36	38.37	15.35	297.98	39.51	25.96	190.30	56.95	26.33	34.37	36.13
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.72%	3.26%	1.70%
Earnings Yield	1.58%	2.61%	6.52%	0.34%	2.53%	3.85%	0.53%	1.76%	3.80%	2.91%	2.77%
Enterprise Value to Invested Capital (EV/IC)	31.95	52.79	13.70	18.60	28.37	21.97	22.17	48.45	17.81	18.26	18.58
Enterprise Value to Revenue (EV/Rev)	7.19	8.29	2.62	5.31	7.05	5.29	6.57	11.21	5.25	8.25	8.78
Enterprise Value to EBITDA (EV/EBITDA)	35.55	21.06	7.14	45.31	29.40	19.81	288.85	41.68	16.61	24.04	25.61
Enterprise Value to EBIT (EV/EBIT)	37.30	22.52	7.77	87.78	34.64	22.54	0.00	47.64	17.30	24.89	26.48
Enterprise Value to NOPAT (EV/NOPAT)	54.02	35.16	11.82	266.53	35.16	22.13	0.00	50.35	22.59	34.15	36.93
Enterprise Value to Operating Cash Flow (EV/OCF)	38.60	34.25	9.04	35.88	29.11	19.92	35.85	41.62	27.87	40.18	25.08
Enterprise Value to Free Cash Flow (EV/FCFF)	87.80	43.58	14.30	1,534.96	41.86	27.16	0.00	51.83	44.07	281.19	51.61
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.76	-0.84	-0.82	-0.80	-0.81	-0.83	-0.84	-0.86	-0.83	-0.69	-0.59
Leverage Ratio	1.15	1.11	1.14	1.18	1.17	1.18	1.18	1.15	1.15	1.22	1.20
Compound Leverage Factor	1.15	1.11	1.14	1.18	1.17	1.18	1.18	1.15	1.15	1.22	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	34.65	55.90	16.09	17.09	25.81	16.13	18.30	32.46	20.11	20.02	39.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.74	11.76	9.25	8.61	9.50	10.06	12.96	11.18	9.06	4.65	8.84
Quick Ratio	8.49	10.68	8.04	7.39	8.23	9.14	11.50	9.91	8.33	3.80	7.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1.28	6.01	5.95	0.08	5.13	7.50	-0.66	9.04	6.35	1.92	12
Operating Cash Flow to CapEx	480.99%	2,429.60%	617.09%	414.17%	2,786.93%	2,106.32%	913.63%	1,517.76%	535.61%	168.16%	290.63%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.03	1.08	0.90	0.61	0.70	0.67	0.46	0.54	0.63	0.74	0.77
Accounts Receivable Turnover	7.94	10.85	8.51	6.11	7.62	6.70	5.34	8.61	5.79	5.14	6.43
Inventory Turnover	1.96	2.59	1.96	1.38	1.74	2.29	2.15	2.37	2.49	1.69	1.45
Fixed Asset Turnover	27.90	37.16	27.52	13.88	16.28	19.63	15.20	19.96	23.85	11.22	5.61
Accounts Payable Turnover	6.44	7.15	5.79	6.27	10.09	9.98	9.87	13.56	9.31	8.43	9.00
Days Sales Outstanding (DSO)	45.96	33.64	42.90	59.73	47.90	54.50	68.29	42.39	63.04	70.98	56.76
Days Inventory Outstanding (DIO)	185.81	140.90	185.91	265.32	209.29	159.42	169.78	153.89	146.80	215.51	250.90
Days Payable Outstanding (DPO)	56.64	51.08	63.05	58.24	36.17	36.56	37.00	26.91	39.20	43.32	40.55
Cash Conversion Cycle (CCC)	175.13	123.46	165.76	266.81	221.02	177.36	201.07	169.36	170.63	243.17	267.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	3.52	4.96	6.21	6.59	7.57	9.27	9.41	9.67	16	30	35
Invested Capital Turnover	5.01	7.45	5.82	3.61	4.30	4.57	3.40	4.38	4.20	2.89	2.28
Increase / (Decrease) in Invested Capital	0.80	1.44	1.25	0.38	0.98	1.71	0.13	0.27	6.04	14	4.95
Enterprise Value (EV)	113	262	85	123	215	204	209	469	280	541	643
Market Capitalization	130	289	111	149	249	250	261	531	338	591	695
Book Value per Share	$1.93	$2.88	$2.98	$3.12	$3.84	$4.83	$5.00	$5.85	$5.86	$5.67	$6.85
Tangible Book Value per Share	$1.91	$2.87	$2.89	$3.04	$3.76	$4.76	$4.92	$5.76	$5.70	$5.47	$6.61
Total Capital	21	32	32	33	42	56	61	72	74	71	87
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-17	-27	-26	-26	-34	-46	-52	-63	-58	-50	-52
Capital Expenditures (CapEx)	0.61	0.31	1.52	0.82	0.26	0.49	0.64	0.74	1.87	8.01	8.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	2.52	4.09	4.52	4.69	5.47	6.85	6.84	6.92	11	9.91	14
Debt-free Net Working Capital (DFNWC)	20	31	30	31	40	53	59	69	69	60	67
Net Working Capital (NWC)	20	31	30	31	40	53	59	69	69	60	67
Net Nonoperating Expense (NNE)	0.03	-0.08	-0.02	-0.04	-0.20	-0.42	-1.90	-0.02	-0.44	-1.35	-1.83
Net Nonoperating Obligations (NNO)	-17	-27	-26	-26	-34	-46	-52	-63	-58	-42	-52
Total Depreciation and Amortization (D&A)	0.15	0.81	0.96	1.31	1.11	1.24	1.34	1.41	0.67	0.77	0.82
Debt-free, Cash-free Net Working Capital to Revenue	16.12%	12.96%	13.89%	20.31%	17.99%	17.80%	21.57%	16.55%	20.59%	15.12%	19.79%
Debt-free Net Working Capital to Revenue	127.08%	98.33%	92.92%	134.43%	130.92%	137.87%	185.45%	166.02%	129.33%	91.02%	91.11%
Net Working Capital to Revenue	127.08%	98.33%	92.92%	134.43%	130.92%	137.87%	185.45%	166.02%	129.33%	91.02%	91.11%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.23	$0.68	$0.67	$0.05	$0.59	$0.85	$0.11	$0.76	$1.02	$1.36	$1.52
Adjusted Weighted Average Basic Shares Outstanding	8.74M	11.00M	10.82M	10.64M	10.76M	11.28M	12.12M	12.35M	12.56M	12.60M	12.67M
Adjusted Diluted Earnings per Share	$0.20	$0.60	$0.60	$0.04	$0.52	$0.78	$0.11	$0.74	$1.02	$1.35	$1.50
Adjusted Weighted Average Diluted Shares Outstanding	10.22M	12.56M	11.99M	11.72M	12.11M	12.28M	12.44M	12.59M	12.64M	12.72M	12.78M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	10.97M	11.03M	10.74M	10.60M	11.00M	11.92M	12.31M	12.56M	12.59M	12.66M	12.72M
Normalized Net Operating Profit after Tax (NOPAT)	2.08	7.45	7.19	0.90	4.20	6.05	-0.53	9.31	12	16	17
Normalized NOPAT Margin	13.31%	23.58%	22.13%	3.90%	13.81%	15.72%	-1.67%	22.26%	23.24%	24.17%	23.76%
Pre Tax Income Margin	19.28%	36.83%	33.70%	6.05%	20.36%	23.48%	-1.94%	23.52%	30.36%	33.16%	33.14%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	97.90%	76.91%	71.11%
Augmented Payout Ratio	99.71%	0.00%	138.19%	363.88%	0.00%	0.00%	0.00%	0.00%	97.90%	76.91%	71.11%

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	25.19%	25.70%	26.80%	23.10%	17.42%	13.72%	11.15%	11.04%	11.10%	10.87%	13.84%
EBITDA Growth	14.59%	29.72%	17.37%	41.20%	46.78%	20.68%	17.91%	0.26%	11.08%	12.25%	16.49%
EBIT Growth	51.07%	42.15%	26.77%	51.23%	20.79%	20.55%	18.32%	0.15%	11.66%	13.39%	16.88%
NOPAT Growth	-14.54%	25.58%	21.18%	39.71%	24.09%	19.38%	12.36%	-2.46%	14.13%	14.32%	21.59%
Net Income Growth	-5.63%	36.97%	28.97%	47.86%	23.58%	21.45%	17.26%	-0.35%	13.37%	13.32%	17.81%
EPS Growth	-6.45%	35.00%	26.92%	48.15%	20.69%	18.52%	15.15%	0.00%	14.29%	15.63%	18.42%
Operating Cash Flow Growth	-9.72%	225.77%	114.36%	-64.64%	28.75%	-16.42%	88.93%	554.54%	53.02%	10.53%	16.69%
Free Cash Flow Firm Growth	-175.03%	-637.03%	-221.50%	-296.70%	-260.61%	16.66%	35.47%	107.42%	97.49%	21.80%	-35.34%
Invested Capital Growth	62.44%	85.86%	68.66%	96.22%	88.61%	43.74%	34.35%	13.98%	16.71%	28.16%	32.66%
Revenue Q/Q Growth	10.86%	4.11%	4.23%	2.32%	5.74%	0.84%	1.88%	2.21%	5.80%	0.63%	4.61%
EBITDA Q/Q Growth	-14.17%	13.00%	21.04%	20.28%	-10.78%	-7.09%	18.26%	2.28%	-1.16%	-6.11%	22.72%
EBIT Q/Q Growth	11.00%	-7.52%	21.81%	20.95%	-11.34%	-7.71%	19.56%	2.38%	-1.15%	-6.29%	23.24%
NOPAT Q/Q Growth	-0.59%	-5.55%	24.77%	19.26%	-11.71%	-9.14%	17.44%	3.53%	3.31%	-8.99%	24.91%
Net Income Q/Q Growth	7.19%	-7.28%	22.72%	21.23%	-10.41%	-8.88%	18.49%	3.03%	1.93%	-8.93%	23.18%
EPS Q/Q Growth	7.41%	-6.90%	22.22%	21.21%	-12.50%	-8.57%	18.75%	5.26%	0.00%	-7.50%	21.62%
Operating Cash Flow Q/Q Growth	-22.84%	52.89%	-24.37%	-60.36%	180.93%	-0.75%	70.96%	37.32%	-34.32%	-28.31%	80.48%
Free Cash Flow Firm Q/Q Growth	-20.11%	-151.09%	19.11%	-62.60%	-9.19%	41.97%	37.36%	118.69%	-136.88%	-1,710.86%	-8.40%
Invested Capital Q/Q Growth	10.81%	37.24%	7.48%	20.05%	6.51%	4.59%	0.46%	1.85%	9.06%	14.86%	3.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.49%	75.74%	75.55%	77.78%	76.86%	76.07%	78.14%	77.44%	76.13%	76.08%	78.17%
EBITDA Margin	26.98%	29.29%	34.01%	39.98%	33.73%	31.08%	36.08%	36.10%	33.73%	31.47%	36.92%
Operating Margin	28.62%	25.89%	30.77%	35.78%	29.57%	26.98%	31.39%	31.59%	29.91%	27.84%	33.26%
EBIT Margin	31.65%	28.11%	32.85%	38.83%	32.56%	29.80%	34.97%	35.02%	32.72%	30.47%	35.90%
Profit (Net Income) Margin	24.72%	22.01%	25.91%	30.70%	26.01%	23.51%	27.34%	27.55%	26.54%	24.03%	28.29%
Tax Burden Percent	78.10%	78.31%	78.89%	79.07%	79.90%	78.89%	78.18%	78.67%	81.12%	78.84%	78.80%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	21.90%	21.69%	21.11%	20.93%	20.10%	21.11%	21.82%	21.33%	18.88%	21.16%	21.20%
Return on Invested Capital (ROIC)	93.87%	69.05%	78.74%	84.83%	68.31%	54.83%	62.78%	59.53%	55.36%	46.65%	56.18%
ROIC Less NNEP Spread (ROIC-NNEP)	93.29%	68.48%	78.20%	84.06%	67.47%	53.94%	61.72%	58.53%	54.42%	45.80%	55.34%
Return on Net Nonoperating Assets (RNNOA)	-77.05%	-50.58%	-56.80%	-59.60%	-46.39%	-33.75%	-39.17%	-36.47%	-32.33%	-26.31%	-32.30%
Return on Equity (ROE)	16.82%	18.47%	21.94%	25.24%	21.92%	21.07%	23.61%	23.06%	23.02%	20.34%	23.88%
Cash Return on Invested Capital (CROIC)	50.03%	18.52%	23.18%	6.67%	8.49%	26.72%	33.05%	43.45%	38.78%	26.05%	24.08%
Operating Return on Assets (OROA)	20.03%	21.45%	25.03%	29.29%	24.03%	24.65%	28.35%	27.50%	25.16%	24.14%	28.38%
Return on Assets (ROA)	15.65%	16.79%	19.75%	23.16%	19.20%	19.45%	22.17%	21.63%	20.41%	19.03%	22.37%
Return on Common Equity (ROCE)	16.82%	18.47%	21.94%	25.24%	21.92%	21.07%	23.61%	23.06%	23.02%	20.34%	23.88%
Return on Equity Simple (ROE_SIMPLE)	0.00%	21.37%	21.29%	21.90%	0.00%	23.55%	23.40%	22.33%	0.00%	21.97%	0.00%
Net Operating Profit after Tax (NOPAT)	3.32	3.14	3.92	4.67	4.12	3.75	4.40	4.55	4.71	4.28	5.35
NOPAT Margin	22.35%	20.28%	24.27%	28.29%	23.62%	21.29%	24.54%	24.85%	24.27%	21.95%	26.21%
Net Nonoperating Expense Percent (NNEP)	0.58%	0.57%	0.54%	0.78%	0.84%	0.89%	1.06%	1.01%	0.94%	0.85%	0.84%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	5.77%	-	-	-	5.42%	4.76%	5.67%
Cost of Revenue to Revenue	24.51%	24.26%	24.45%	22.22%	23.14%	23.93%	21.86%	22.56%	23.87%	23.92%	21.83%
SG&A Expenses to Revenue	18.14%	25.33%	20.54%	21.90%	24.49%	22.68%	22.90%	21.65%	19.98%	23.63%	20.97%
R&D to Revenue	4.07%	19.39%	5.96%	2.74%	-8.91%	21.75%	4.47%	3.49%	-12.56%	3.20%	4.30%
Operating Expenses to Revenue	46.87%	49.85%	44.78%	42.00%	47.29%	49.09%	46.75%	45.85%	46.21%	48.24%	44.92%
Earnings before Interest and Taxes (EBIT)	4.70	4.35	5.30	6.41	5.68	5.24	6.27	6.42	6.34	5.95	7.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.01	4.53	5.49	6.60	5.89	5.47	6.47	6.62	6.54	6.14	7.53
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.59	7.54	8.53	7.34	8.27	7.27	6.96	7.64	8.00	7.41	8.06
Price to Tangible Book Value (P/TBV)	4.72	7.81	8.84	7.60	8.58	7.53	7.21	7.91	8.30	7.69	8.36
Price to Revenue (P/Rev)	6.34	8.60	9.84	8.70	9.01	8.17	7.98	8.94	9.49	8.88	9.79
Price to Earnings (P/E)	26.33	35.30	40.10	33.54	34.37	30.87	29.75	34.21	36.13	33.73	36.80
Dividend Yield	3.72%	2.72%	2.25%	2.42%	3.26%	3.50%	1.44%	1.55%	1.70%	1.18%	1.07%
Earnings Yield	3.80%	2.83%	2.49%	2.98%	2.91%	3.24%	3.36%	2.92%	2.77%	2.97%	2.72%
Enterprise Value to Invested Capital (EV/IC)	17.81	20.52	23.43	18.00	18.26	16.39	16.25	18.46	18.58	15.53	17.12
Enterprise Value to Revenue (EV/Rev)	5.25	7.84	9.07	7.95	8.25	7.51	7.28	8.21	8.78	8.21	9.11
Enterprise Value to EBITDA (EV/EBITDA)	16.61	24.74	29.04	24.28	24.04	21.68	20.72	23.95	25.61	23.95	26.36
Enterprise Value to EBIT (EV/EBIT)	17.30	25.33	29.21	24.13	24.89	22.45	21.44	24.79	26.48	24.70	27.16
Enterprise Value to NOPAT (EV/NOPAT)	22.59	33.96	39.60	33.30	34.15	30.88	29.88	34.80	36.93	34.39	37.44
Enterprise Value to Operating Cash Flow (EV/OCF)	27.87	33.37	35.88	39.78	40.18	40.00	31.97	24.86	25.08	23.70	26.06
Enterprise Value to Free Cash Flow (EV/FCFF)	44.07	144.13	126.94	357.68	281.19	72.36	56.38	45.27	51.61	66.98	81.09
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.83	-0.74	-0.73	-0.71	-0.69	-0.63	-0.63	-0.62	-0.59	-0.57	-0.58
Leverage Ratio	1.15	1.17	1.17	1.16	1.22	1.17	1.15	1.15	1.20	1.14	1.13
Compound Leverage Factor	1.15	1.17	1.17	1.16	1.22	1.17	1.15	1.15	1.20	1.14	1.13
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	19.66	28.31	30.95	28.19	19.45	30.51	35.04	37.97	38.82	36.83	40.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.06	9.07	8.71	9.13	4.65	9.44	9.87	9.21	8.84	8.87	8.78
Quick Ratio	8.33	8.04	7.50	7.55	3.80	7.64	8.11	7.70	7.38	7.44	7.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2.72	-6.82	-5.52	-8.97	-9.80	-5.69	-3.56	0.67	-0.25	-4.45	-4.82
Operating Cash Flow to CapEx	644.27%	70.86%	928.79%	317.22%	618.27%	811.01%	522.81%	227.24%	195.87%	109.57%	274.33%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.76	0.76	0.75	0.74	0.83	0.81	0.79	0.77	0.79	0.79
Accounts Receivable Turnover	5.79	6.26	6.15	5.37	5.14	5.51	6.03	6.16	6.43	5.84	6.79
Inventory Turnover	2.49	2.41	2.14	1.77	1.69	1.67	1.55	1.42	1.45	1.49	1.54
Fixed Asset Turnover	23.85	10.46	10.93	11.27	11.22	7.48	7.24	6.19	5.61	5.04	4.65
Accounts Payable Turnover	9.31	8.88	8.42	8.01	8.43	10.43	8.62	7.79	9.00	8.95	11.84
Days Sales Outstanding (DSO)	63.04	58.32	59.33	67.91	70.98	66.22	60.50	59.25	56.76	62.49	53.77
Days Inventory Outstanding (DIO)	146.80	151.44	170.51	205.64	215.51	218.72	236.09	256.56	250.90	244.59	237.47
Days Payable Outstanding (DPO)	39.20	41.11	43.35	45.57	43.32	35.00	42.33	46.83	40.55	40.77	30.84
Cash Conversion Cycle (CCC)	170.63	168.66	186.49	227.99	243.17	249.94	254.26	268.98	267.11	266.31	260.40
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	22	23	28	30	31	31	32	35	40	41
Invested Capital Turnover	4.20	3.41	3.24	3.00	2.89	2.58	2.56	2.40	2.28	2.13	2.14
Increase / (Decrease) in Invested Capital	6.04	9.96	9.43	14	14	9.43	7.96	3.89	4.95	8.73	10
Enterprise Value (EV)	280	443	543	501	541	508	506	585	643	617	707
Market Capitalization	338	485	589	548	591	553	555	637	695	667	760
Book Value per Share	$5.86	$5.11	$5.48	$5.92	$5.67	$6.01	$6.29	$6.59	$6.85	$7.08	$7.42
Tangible Book Value per Share	$5.70	$4.93	$5.29	$5.72	$5.47	$5.80	$6.07	$6.36	$6.61	$6.83	$7.15
Total Capital	74	64	69	75	71	76	80	83	87	90	94
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-58	-43	-46	-47	-50	-45	-49	-52	-52	-50	-53
Capital Expenditures (CapEx)	0.47	6.56	0.38	0.44	0.63	0.48	1.27	4.01	3.06	3.92	2.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	11	12	13	17	9.91	19	18	15	14	16	16
Debt-free Net Working Capital (DFNWC)	69	55	59	64	60	64	66	66	67	67	69
Net Working Capital (NWC)	69	55	59	64	60	64	66	66	67	67	69
Net Nonoperating Expense (NNE)	-0.35	-0.27	-0.26	-0.40	-0.42	-0.39	-0.50	-0.50	-0.44	-0.41	-0.42
Net Nonoperating Obligations (NNO)	-58	-43	-46	-47	-42	-45	-49	-52	-52	-50	-53
Total Depreciation and Amortization (D&A)	-0.69	0.18	0.19	0.19	0.21	0.23	0.20	0.20	0.19	0.19	0.21
Debt-free, Cash-free Net Working Capital to Revenue	20.59%	20.84%	21.18%	27.48%	15.12%	28.28%	25.31%	20.34%	19.79%	21.73%	20.05%
Debt-free Net Working Capital to Revenue	129.33%	96.59%	97.71%	101.71%	91.02%	94.95%	95.16%	92.87%	91.11%	88.70%	88.31%
Net Working Capital to Revenue	129.33%	96.59%	97.71%	101.71%	91.02%	94.95%	95.16%	92.87%	91.11%	88.70%	88.31%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.29	$0.27	$0.33	$0.40	$0.36	$0.33	$0.39	$0.40	$0.40	$0.37	$0.45
Adjusted Weighted Average Basic Shares Outstanding	12.56M	12.59M	12.60M	12.60M	12.60M	12.66M	12.66M	12.67M	12.67M	12.71M	12.72M
Adjusted Diluted Earnings per Share	$0.29	$0.27	$0.33	$0.40	$0.35	$0.32	$0.38	$0.40	$0.40	$0.37	$0.45
Adjusted Weighted Average Diluted Shares Outstanding	12.64M	12.69M	12.72M	12.74M	12.72M	12.75M	12.76M	12.78M	12.78M	12.83M	12.84M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.59M	12.59M	12.60M	12.61M	12.66M	12.66M	12.67M	12.67M	12.72M	12.72M	12.72M
Normalized Net Operating Profit after Tax (NOPAT)	3.32	3.14	3.92	4.67	4.12	3.75	4.40	4.55	4.71	4.28	5.35
Normalized NOPAT Margin	22.35%	20.28%	24.27%	28.29%	23.62%	21.29%	24.54%	24.85%	24.27%	21.95%	26.21%
Pre Tax Income Margin	31.65%	28.11%	32.85%	38.83%	32.56%	29.80%	34.97%	35.02%	32.72%	30.47%	35.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	97.90%	96.18%	90.03%	80.99%	76.91%	44.50%	52.97%	63.22%	71.11%	39.74%	39.33%
Augmented Payout Ratio	97.90%	96.18%	90.03%	80.99%	76.91%	44.50%	52.97%	63.22%	71.11%	39.74%	39.33%

Financials Breakdown Chart

Key Financial Trends

iRadimed (NASDAQ: IRMD) Financial Overview (Q2 2022 - Q2 2025):

Over the past three years, iRadimed has demonstrated consistent revenue growth, improved profitability, and maintained a strong balance sheet position with solid cash reserves. Below is a summary of the key financial trends based on quarterly data analysis from Q2 2022 through Q2 2025.

Operating Revenue Growth: Revenue increased from approximately $12.7 million in Q2 2022 to over $20.4 million in Q2 2025, representing a steady upward trend in sales.
Consistent Net Income Growth: Net income from continuing operations rose from $3.24 million in Q2 2022 to $5.77 million in Q2 2025, reflecting improving profitability.
Improved Gross Profit Margins: Gross profit grew in line with revenue, reaching nearly $16 million in Q2 2025, suggesting good cost controls on the cost of revenue which remained below 22% of sales.
Increasing Earnings Per Share (EPS): Basic and diluted EPS grew from around $0.26 in Q2 2022 to $0.45 in Q2 2025, indicating shareholder value growth with relatively stable share count.
Strong Operating Cash Flow: Net cash from operating activities surged to approximately $7.7 million in Q2 2025 from $1.6 million in Q2 2022, demonstrating improving cash generation capabilities.
Stable and Growing Cash Reserves: Cash and equivalents increased from about $52 million in Q2 2022 to nearly $53 million in Q2 2025, underscoring liquidity strength despite investments and dividends.
Controlled Operating Expenses: Although operating expenses have increased in absolute terms, as a percentage of revenue, they remain controlled, helping to boost operating income.
Regular Dividend Payments: The company has maintained dividend payments quarterly, supporting shareholder returns with payments over $2 million in recent quarters.
Capital Investment for Growth: Significant purchases in property, plant, and equipment, notably over $2.8 million in Q2 2025, indicate ongoing investment in operational capacity.
Fluctuating Marketing and R&D Expenses: Marketing and research & development costs have shown some volatility including a notable negative R&D expense in Q4 2024, which could represent adjustments or atypical accounting impacts rather than cash outlays.
Changes in Working Capital: Changes in operating assets and liabilities have varied considerably quarter-to-quarter, affecting operating cash flow but possibly reflecting normal business cycle dynamics.

Moderate Increase in Current Liabilities: Total current liabilities have generally increased, reaching $8.8 million in Q2 2025 compared to $6.1 million in Q2 2022, indicating higher short-term obligations which investors should monitor.
Decline in Accounts Receivable and Inventories in some periods: While inventory and receivables generally grew, some quarters show declines which could indicate sales fluctuations or supply chain impacts.
Large Negative Free Cash Flow in Early 2023: Q1 2023 cash flow from financing activities showed a heavy outflow of $13.3 million due to dividend payments which significantly reduced cash, suggesting aggressive capital return at that period.

Summary: iRadimed has experienced solid financial growth with rising revenues, net income, and EPS over the last three years. The company is generating healthy operating cash flows and retains a strong cash position to fund continued investments and dividends. Minor fluctuations in expenses and current liabilities warrant monitoring, but overall the financial trajectory is positive, supporting potential value creation for shareholders.

09/21/25 01:28 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About iRadimed's Financials

When does iRadimed's financial year end?

According to the most recent income statement we have on file, iRadimed's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has iRadimed's net income changed over the last 10 years?

iRadimed's net income appears to be on an upward trend, with a most recent value of $19.23 million in 2024, rising from $2.05 million in 2014. The previous period was $17.19 million in 2023. See where experts think iRadimed is headed by visiting iRadimed's forecast page.

What is iRadimed's operating income?

iRadimed's total operating income in 2024 was $21.96 million, based on the following breakdown:

Total Gross Profit: $56.35 million
Total Operating Expenses: $34.39 million

How has iRadimed's revenue changed over the last 10 years?

Over the last 10 years, iRadimed's total revenue changed from $15.65 million in 2014 to $73.24 million in 2024, a change of 367.9%.

How much debt does iRadimed have?

iRadimed's total liabilities were at $11.51 million at the end of 2024, a 44.5% decrease from 2023, and a 375.7% increase since 2014.

How much cash does iRadimed have?

In the past 10 years, iRadimed's cash and equivalents has ranged from $9.45 million in 2014 to $62.00 million in 2021, and is currently $52.23 million as of their latest financial filing in 2024.

How has iRadimed's book value per share changed over the last 10 years?

Over the last 10 years, iRadimed's book value per share changed from 1.93 in 2014 to 6.85 in 2024, a change of 254.6%.

Related Companies

This page (NASDAQ:IRMD) was last updated on 9/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About iRadimed's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Financials

Annual Income Statements for iRadimed

Quarterly Income Statements for iRadimed

Annual Cash Flow Statements for iRadimed

Quarterly Cash Flow Statements for iRadimed

Annual Balance Sheets for iRadimed

Quarterly Balance Sheets for iRadimed

Annual Metrics And Ratios for iRadimed

Quarterly Metrics And Ratios for iRadimed

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About iRadimed's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools